Novartis has opened an investigation after learning that a company employee was affiliated with a study of its blood pressure drug Diovan as a statistician without revealing his ties to the Swiss healthcare giant.
Turns out, Everolimus is becoming quite the franchise for Novartis ($NVS). It just nabbed another approval, this time as Zortress, to prevent organ rejection in liver transplant patients.
Flat sales and lower profits. These aren't predictions that shareholders like to hear. But like other Big Pharmas before it, Novartis faces generic competition for its biggest drugs. And like its rivals, the Swiss drugmaker is bracing for continued fallout.
While FiercePharma 's newsletter went on hiatus over the winter holidays--and industry news slowed to a pace suitable to hibernation-friendly weather--we didn't spend all our time skiing and drinking cocoa. Some certifiably big news broke last week. Here are several holiday highlights.
It is another swing and a miss for Mylan. Twice now it has struck out in efforts to snatch away from Ranbaxy Laboratories the Indian drugmaker's 180-day exclusivity on a drug.
Generic drugmaker Mylan ($MYL), impatient that money is sitting on the table, has sued the FDA to try to snatch the rights to produce a generic of Novartis' ($NVS) blockbuster blood pressure med, Diovan.
When it comes to news releases, CEOs can't control the conversation. No doubt Novartis ($NVS) Chief Joe Jimenez would like to tell reporters, "Diovan may be dying but our new drugs don't need therapy--Discuss."
Novartis ($NVS) CEO Joe Jimenez isn't shy about holding up a "warning" sign. In an interview with Switzerland's Sonntags Zeitung over the weekend, Jimenez once again reminded folks to expect no fireworks from Novartis in the near term.
Mylan ($MYL) has sued FDA for the right to sell a version of Novartis' ($NVS) blood pressure drug Diovan--right now. India's Ranbaxy Laboratories may have exclusive rights to market copycat Diovan for 6 months, Mylan figures, but Novartis' patent expired more than two weeks ago, and Ranbaxy's copy is MIA.
Pfizer's success with co-pay coupons has encouraged other blockbuster-losing Big Pharmas to follow suit. Have the others been able to replicate Pfizer's experience? Yes and no, according to the Associated Press .